In human dermal safety studies, tazarotene 0.05% and 0.1% creams did not induce
allergic contact sensitization, phototoxicity or photoallergy.
The most frequent treatment-related adverse reactions ( ≥ 5%) reported during
the clinical trials with AVAGE® (TAZAROTENE) Cream 0.1% in the treatment
of facial fine wrinkling, mottled hypo- and hyperpigmentation, and benign facial
lentigines were limited to the skin. Those occurring in >10%, in descending
order, included: desquamation, erythema, burning sensation, and dry skin. Events
occurring in ≥ 1% to ≤ 10% of patients, in descending order included: skin
irritation, pruritus, irritant contact dermatitis, stinging, acne, rash or cheilitis.
Common adverse events observed in the clinical trials are presented in the following
table:
TABLE OF ADVERSE EVENTS SEEN IN CLINICAL TRIALS WITH AVAGE®
(TAZAROTENE) Cream 0.1%
| Adverse Event |
AVAGE ®
N=567 |
Vehicle
N=564 |
| Desquamation |
40% |
3% |
| Erythema |
34% |
3% |
| BurningSensation |
26% |
<1% |
| DrySkin |
16% |
3% |
| Irritation Skin |
10% |
1% |
| Pruritus |
10% |
1% |
| Irritant Contact Dermatitis |
8% |
1% |
| Stinging |
3% |
<1% |
| Acne |
3% |
3% |
| Rash |
3% |
1% |
| Cheilitis |
1% |
0% |
A few patients reported adverse events at Week 0; however, for patients who
were treated with AVAGE® (tazarotene) the highest number of new reports for each adverse
event was at Week 2.
When combining data from the two pivotal studies, 5.3% of patients in the tazarotene
cream group and 0.9% of patients in the vehicle group discontinued due to adverse
events.
Overall, 20/567 (3.5%) patients in the AVAGE® (TAZAROTENE) Cream 0.1% group
and 16/564 (2.8%) patients in the vehicle group reported adverse events (including
edema, irritation, and inflammation) directly related to the eye or eyelid.
The majority of these conditions were mild.